A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0

Objectives To investigate the association between lower urinary-tract infections, their associated antibiotics and the subsequent risk of developing PCa. Subjects/Patients (or materials) and methods Using data from the Swedish PCBaSe 3.0, we performed a matched case-control study (8762 cases and 43806 controls). Conditional logistic regression analysis was used to assess the association between lower urinary-tract infections, related antibiotics and PCa, whilst adjusting for civil status, education, Charlson Comorbidity Index and time between lower urinary-tract infection and PCa diagnosis. Results It was found that lower urinary-tract infections did not affect PCa risk, however, having a lower urinary-tract infection or a first antibiotic prescription 6–12 months before PCa were both associated with an increased risk of PCa (OR: 1.50, 95% CI: 1.23–1.82 and 1.96, 1.71–2.25, respectively), as compared to men without lower urinary-tract infections. Compared to men with no prescriptions for antibiotics, men who were prescribed ≥10 antibiotics, were 15% less likely to develop PCa (OR: 0.85, 95% CI: 0.78–0.91). Conclusion PCa was not found to be associated with diagnosis of a urinary-tract infection or frequency, but was positively associated with short time since diagnoses of lower urinary-tract infection or receiving prescriptions for antibiotics. These observations can likely be explained by detection bias, which highlights the importance of data on the diagnostic work-up when studying potential risk factors for PCa.

[1]  J. B. Gregg,et al.  DEPARTMENT OF HEALTH. , 1910, California state journal of medicine.

[2]  P. Stattin,et al.  Human Papillomavirus 16, 18, and 33 Infections and Risk of Prostate Cancer: A Nordic Nested Case-Control Study , 2005, Cancer Epidemiology Biomarkers & Prevention.

[3]  Jie Lin,et al.  Urinary tract diseases and bladder cancer risk: a case–control study , 2007, Cancer Causes & Control.

[4]  D. English,et al.  Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case–control study , 2010, British Journal of Cancer.

[5]  P. Stattin,et al.  Chlamydial Antibodies and Risk of Prostate Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[6]  W. Willett,et al.  Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[7]  Jennifer R. Rider,et al.  Frequency and typing of Propionibacterium acnes in prostate tissue obtained from men with and without prostate cancer , 2016, Infectious Agents and Cancer.

[8]  P. Stattin,et al.  Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory , 2015, International journal of epidemiology.

[9]  E. Negri,et al.  Genital and urinary tract diseases and prostate cancer risk , 2006, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[10]  W. Stamm Scientific and clinical challenges in the management of urinary tract infections. , 2002, The American journal of medicine.

[11]  J. Vijayakumar,et al.  Correlation of Prostate Gland Size and Uroflowmetry in Patients with Lower Urinary Tract Symptoms. , 2017, Journal of clinical and diagnostic research : JCDR.

[12]  J. McNeal,et al.  Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? , 2005, The Journal of urology.

[13]  A. L. Conte,et al.  Features of uropathogenic Escherichia coli able to invade a prostate cell line. , 2016, The new microbiologica.

[14]  M. Nowicki,et al.  New markers of urinary tract infection. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[15]  S. Miyamoto,et al.  Chemopreventive effects of a low-side-effect antibiotic drug, erythromycin, on mouse intestinal tumors , 2017, Journal of clinical biochemistry and nutrition.

[16]  P. Stattin,et al.  Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. , 2013, International journal of epidemiology.

[17]  F. Saad,et al.  Prostatitis, other genitourinary infections and prostate cancer: results from a population-based case–control study , 2016, World Journal of Urology.

[18]  Cheng-Li Lin,et al.  Lower Urinary Tract Infection and Subsequent Risk of Prostate Cancer: A Nationwide Population-Based Cohort Study , 2017, PloS one.

[19]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[20]  A. D. De Marzo,et al.  Prostate cancer and inflammation: the evidence , 2012, Histopathology.